QuidelOrtho Announces Separation of Chairman and Chief Executive Officer Roles

Author's Avatar
Dec 12, 2022

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”), a global provider of innovative in vitro diagnostic (IVD) technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that its Board of Directors (the “Board”) has appointed Dr. Kenneth F. Buechler, Lead Independent Director, to non-executive Chairman, effective December 11, 2022. The separation of the Chairman and Chief Executive Officer roles is a key step toward strengthening the Company’s governance practices and will facilitate the right balance between strong and consistent Company leadership and independent oversight by the Board. The Board also appointed Douglas Bryant to serve as President, in addition to Mr. Bryant’s current role as Chief Executive Officer and a member of the Board.